Company news

Crinetics Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 9, 2025

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 26, 2025

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

February 23, 2025

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

February 19, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 9, 2025

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 5, 2025

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2025

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

January 9, 2025

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

December 15, 2024

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 9, 2024

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

December 8, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

November 14, 2024

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

November 11, 2024

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2024

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

October 15, 2024

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2024

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

October 7, 2024

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

September 25, 2024

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2024

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

August 28, 2024

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2024

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

August 7, 2024

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

July 17, 2024

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 9, 2024

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2024

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

June 2, 2024

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

June 2, 2024

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

May 29, 2024

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

May 21, 2024

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2024

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

May 7, 2024

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2024

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

March 18, 2024

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

March 11, 2024

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2024

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 27, 2024

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

February 27, 2024

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

February 13, 2024

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2024

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2024

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

December 17, 2023

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2023

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

November 19, 2023

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 9, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.